Download PDF
Thromb Haemost 2002; 88(05): 871-872
DOI: 10.1055/s-0037-1613316
Letters to the Editor
Schattauer GmbH

A Collagen Binding Assay: An Additional Method for von Willebrand Factor Activity in Therapeutic Concentrates

B.M. Neugebauer
1   Paul-Ehrlich-Institut, Div. Haematology and Transfusion Medicine, Langen, Germany; on behalf of the European Pharmacopoeia Expert Group 6B
,
C. Goy
1   Paul-Ehrlich-Institut, Div. Haematology and Transfusion Medicine, Langen, Germany; on behalf of the European Pharmacopoeia Expert Group 6B
,
R. Seitz
1   Paul-Ehrlich-Institut, Div. Haematology and Transfusion Medicine, Langen, Germany; on behalf of the European Pharmacopoeia Expert Group 6B
› Author Affiliations
Further Information

Publication History

Received 10 March 2002

Accepted after resubmission 23 July 2002

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Favaloro EJ. Collagen binding assay for von Willebrand factor (vWF:CBA): Detection of von Willebrand disease (vWD), and discrimination of vWD subtypes, depends on the collagen source. Thromb Haemost 2000; 83: 127-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia 1998; (Suppl. 03) 15-24.
    PubMedGoogle Scholar
  • 3 Brown JE, Bosak JO. An ELBA for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
    CrossrefPubMedGoogle Scholar
  • 4 Thomas KB, Choong SC, Jessat U. et al. Platelet von Willebrand factor-collagen binding activity and ristocetin cofactor activity: a comparison of methods able to differentiate von Willebrand disease types I and II (preliminary results). In: Scharrer I, Schramm W. eds 24. Hämophilie Symposium Hamburg 1993. Berlin, Heidelberg: Springer-Verlag; 1994: 234-42.
    Google Scholar
  • 5 Neugebauer BM, Goy C, Budek I, Seitz R. Comparison of two von Willebrand Factor Collagen Binding Assays with Different Binding Affinities for Low, Medium and High Multimers of von Willebrand Factor. Sem Thromb Hemost 2002; 28: 139-47.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Fischer BE, Kramer G, Mitterer A. et al. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thrombosis Research 1996; 84: 55-66.
    CrossrefPubMedGoogle Scholar
  • 7 Metzner HJ, Hermentin P, Cuesta-Linker T. et al. Characterisation of factor VHI/von Willebrand factor concentrates using a modified method of von Willebrand multimer analysis. Haemophilia 1998; 04 (Suppl. 03) 25-32.
    CrossrefPubMedGoogle Scholar
  • 8 Mannucci PM. Treatment of von Willebrand disease. Thromb Haemostas 2001; 86: 149-53.
    PubMedGoogle Scholar
  • 9 Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 2001; 07 (Suppl. 01) 10-5.
    CrossrefPubMedGoogle Scholar
  • 10 Neugebauer BM, Volkers P, Seitz R. von Willebrand Factor Potency Determination by Collagen Binding Assay. A Collaborative Study for the Establishment of a European Pharmacopoeia Method. PharmEuropa 2002; 14.2: 315-27.
    PubMedGoogle Scholar
  • 11 Assay of human von Willebrand factor. PharmEuropa 2002; 14.2: 377-8.
    PubMedGoogle Scholar